Anileridine
Analgesic drug
- N01AH05 (WHO)
- AU: S8 (Controlled drug)
- BR: Class A1 (Narcotic drugs)[1]
- CA: Schedule I
- DE: Anlage I (Authorized scientific use only)
- US: Schedule II
- Ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate
- 144-14-9
Y
- 8944
- 7115
- DB00913 Y
- 8600 Y
- 71Q1A3O279
- D02941 Y
- CHEBI:61203 Y
- ChEMBL1201347
N
- DTXSID8022610
- Interactive image
- O=C(OCC)C3(c1ccccc1)CCN(CCc2ccc(N)cc2)CC3
- InChI=1S/C22H28N2O2/c1-2-26-21(25)22(19-6-4-3-5-7-19)13-16-24(17-14-22)15-12-18-8-10-20(23)11-9-18/h3-11H,2,12-17,23H2,1H3Y
- Key:LKYQLAWMNBFNJT-UHFFFAOYSA-NY
N
Y (what is this?) (verify)Anileridine (trade name: Leritine) is a synthetic analgesic drug[2] and is a member of the piperidine class of analgesic agents[3] developed by Merck & Co. in the 1950s.[4] It differs from pethidine (meperidine) in that the N-methyl group of meperidine is replaced by an N-aminophenethyl group, which increases its analgesic activity.
Anileridine is no longer manufactured in the US or Canada.[5] Anileridine is in Schedule II of the Controlled Substances Act 1970 of the United States as ACSCN 9020 with a zero aggregate manufacturing quota as of 2014. The free base conversion ratio for salts includes 0.83 for the dihydrochloride and 0.73 for the phosphate.[6] It is also under international control per UN treaties.
Administration
As tablets or injection.[7]
Pharmacokinetics
Anileridine usually takes effect within 15 minutes of either oral or intravenous administration, and lasts 2–3 hours.[8] It is mostly metabolized by the liver.
See also
References
- ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- ^ Orahovats PD, Lehman EG, Chapin EW (January 1957). "Pharmacology of ethyl-1-(4-aminophenethyl)-4-phenylisonipecotate, anileridine, a new potent synthetic analgesic". The Journal of Pharmacology and Experimental Therapeutics. 119 (1): 26–34. PMID 13417056.
- ^ Stage JT (August 1957). "Anileridine as an anesthetic agent". The Journal of the Florida Medical Association. Florida Medical Association. 44 (2): 143–5. PMID 13449255.
- ^ US 2897204, Frank A Cutler Jr FA, Chemerda JM, "Substituted piperidines and methods for making same", issued 28 July 1959, assigned to Merck and Co Inc
- ^ "Discontinued Prescription Drug Products". Canadian Pharmacists' Association. Archived from the original on 19 September 2008. Retrieved 28 July 2008.
- ^ "Federal Register Notices: Quotas - 2014". Diversion Control Division, Drug Enforcement Agency. U.S. Department of Justice. 25 August 2014. Archived from the original on 4 March 2016. Retrieved 26 February 2016.
- ^ "Pharmaceutical Information - LERITINE". RxMed. Retrieved 16 June 2010.
- ^ "Anileridine Consumer Information". MedicineNet. Archived from the original on 28 March 2012. Retrieved 28 July 2008.
- v
- t
- e
modulators
| Calcium blockers |
|
|---|---|
| Sodium blockers |
|
| Potassium openers |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This analgesic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
